AbbVie reported that its Phase 3 trial (EPCORE DLBCL-4) evaluating Epcoritamab plus lenalidomide in adults with relapsed or refractory DLBCL met its primary endpoint. The development is a clear clinical efficacy milestone for the program and supports a more constructive outlook for the therapy’s commercialization pathway.
AbbVie reported that its Phase 3 trial (EPCORE DLBCL-4) evaluating Epcoritamab plus lenalidomide in adults with relapsed or refractory DLBCL met its primary endpoint. The development is a clear clinical efficacy milestone for the program and supports a more constructive outlook for the therapy’s commercialization pathway.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
